Viridian Therapeutics VRDN
Valuation
Multiples measured against the stock's own five-year history
Near the bottom of its 5-year range · 12th percentile, 5-year average -4.9x
Above its usual level · 76th percentile, 5-year average 6.0x
#4745 of 5330 stocks by PB (1 = cheapest)
Below its usual level · 21st percentile, 5-year average 1,839.3x
#4979 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 7.26 | – | 6.00 | 76% (pricier than usual) | #4745 of 5330 (1 = cheapest) |
| PE | -8.02 | -11.97 | -4.91 | 12% (cheaper than usual) | – |
| PS | 133.25 | 11.41 | 1,839.27 | 21% (cheaper than usual) | #4979 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on VRDN.
Sign in to join the discussion.